COYA
Coya Therapeutics, Inc.Company Information
- Company Name
- Coya Therapeutics, Inc.
- CIK
- CIK0001835022
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- COYA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- COYA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-14
- Last sale
- —
- Shares purchased (TTM)
- 14,510
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 7,792,932
- Shares outstanding
- 23,457,227
- Ownership
- 33.22%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -0.83%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 43 | 51 | 47 | 28 | 30 | 36 | 38 | 31 | 37 | 36 | 33 | 11 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 3 | 3 | 4 | 4 | 3 | 6 | 4 | 3 | 1 | 1 | 1 | ||||||
| Assets Current | 47 | 53 | 50 | 32 | 33 | 38 | 44 | 36 | 40 | 37 | 41 | 12 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 47 | 53 | 50 | 32 | 33 | 38 | 44 | 36 | 40 | 37 | 41 | 12 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 2 | 2 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 4 | 2 | 3 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | ||||||
| Deferred Revenue Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Liabilities Current | 4 | 4 | 6 | 4 | 5 | 4 | 4 | 2 | 4 | 4 | 5 | 2 | ||||||
| Liabilities | 4 | 4 | 7 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 6 | 2 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 119 | 118 | 105 | 84 | 82 | 81 | 80 | 70 | 69 | 63 | 62 | 37 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | - | - | - | - | 0 | 0 | -0 | -0 | - | ||||||
| Retained Earnings Accumulated Deficit | -76 | -69 | -62 | -56 | -54 | -48 | -41 | -38 | -34 | -31 | -26 | -27 | ||||||
| Stockholders Equity | 43 | 49 | 43 | 27 | 28 | 33 | 40 | 32 | 35 | 32 | 36 | 10 | ||||||
| Liabilities And Stockholders Equity | 47 | 53 | 50 | 32 | 33 | 38 | 44 | 36 | 40 | 37 | 41 | 12 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 23 | 23 | 21 | 17 | 17 | 17 | 17 | 15 | 15 | 15 | 14 | 10 | ||||||
| Shares Outstanding | 23 | 23 | 21 | 17 | 17 | 17 | 17 | 15 | 15 | 15 | 14 | 10 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCoya Therapeutics, Inc. (COYA) — SEC Financial Statements & Analysis
Coya Therapeutics, Inc. (COYA) is a pharmaceutical preparations company, incorporated in DE. Coya Therapeutics, Inc. trades on Nasdaq as: COYA. Coya Therapeutics, Inc. (COYA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Coya Therapeutics, Inc. carries a market cap of $137.22M, a P/E ratio of -6.33x, a P/B ratio of 3.17x, a P/S ratio of 17.11x, an enterprise value of $94.04M, and an EV/EBITDA multiple of -4.07x. On profitability, it posts an operating margin of -288.70%, a net margin of -270.22%, a Return on Equity (ROE) of -60.54%, a Return on Assets (ROA) of -53.66%, and a Return on Invested Capital (ROIC) of -746.79%. Per share, it reports EPS of $-0.92, diluted EPS of $-0.92, free cash flow per share of $-0.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1793.76% year-over-year, net income growth of 6.54% year-over-year, and EPS growth of -24.04% year-over-year. On the balance sheet, it maintains a current ratio of 13.40x, a quick ratio of 12.29x, working capital of $43.55M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.09, free cash flow of $-15.72M (TTM), and net debt of $-43.18M. Figures sourced from SEC EDGAR.
- Market Cap
- $137.22M
- P/E TTM
- -6.33x
- EPS TTM
- $-0.92
- P/B TTM
- 3.17x
- ROE TTM
- -60.54%
- ROA TTM
- -53.66%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-15.72M
- Net Revenue TTM Growth 1Y
- 1793.76%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Coya Therapeutics, Inc. in?
Coya Therapeutics, Inc. (COYA) operates in the Pharmaceutical Preparations industry.
What exchange does COYA trade on?
Coya Therapeutics, Inc. (COYA) trades on the Nasdaq.
Where is Coya Therapeutics, Inc. incorporated?
Coya Therapeutics, Inc. is incorporated in DE.
When was Coya Therapeutics, Inc. (COYA)'s most recent SEC filing?
Coya Therapeutics, Inc. (COYA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is COYA's market cap?
Coya Therapeutics, Inc. (COYA) has a market capitalization of $137.22M as of 2026-06-30.
What is COYA's EPS (earnings per share)?
Coya Therapeutics, Inc. (COYA)'s trailing twelve month EPS is $-0.92 as of 2026-06-30.
What is COYA's ROE (return on equity)?
Coya Therapeutics, Inc. (COYA)'s trailing twelve month Return on Equity (ROE) is -60.54% as of 2026-06-30.
What is COYA's ROA (return on assets)?
Coya Therapeutics, Inc. (COYA)'s trailing twelve month Return on Assets (ROA) is -53.66% as of 2026-06-30.
What is COYA's ROIC (return on invested capital)?
Coya Therapeutics, Inc. (COYA)'s trailing twelve month Return on Invested Capital (ROIC) is -746.79% as of 2024-12-31.
What is COYA's EV/EBITDA?
Coya Therapeutics, Inc. (COYA)'s trailing twelve month EV/EBITDA is -4.07x as of 2026-06-30.